A phase 3 trial of Johnson & Johnson's TAR-200 therapy in bladder cancer has failed to show efficacy, although the company is still confident in the potential of the programme. The SunRISe-2 study ...
Johnson & Johnson has initiated an application seeking Food and Drug Administration approval of its TAR-200 drug-device combination for the treatment of certain patients with bladder cancer.
Johnson & Johnson (NYSE:JNJ) said it has submitted a New Drug Application to the FDA for its therapy candidate TAR-200 for the treatment of a certain type of bladder cancer. The drugmaker is ...
Johnson & Johnson announced it has initiated the submission of an original New Drug Application with the U.S. FDA for TAR-200 for the treatment of patients with Bacillus Calmette-Guerin ...
Raritan: Johnson & Johnson has announced it has initiated the submission of an original New Drug Application with the U.S. Food and Drug Administration (FDA) for TAR-200 for the treatment ...
The J&J filing seeks the FDA’s nod for TAR-200 as a single agent to treat patients with BCG-unresponsive, high-risk NMIBC with carcinoma in-situ (CIS), with or without papillary tumors. If ...